Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

Summary, in English

Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.

• Author: Robert Palmason; Ola Lindén; Johan Richter
• Department/s: Stem Cell Center; Tumor microenvironment; Division of Molecular Medicine and Gene Therapy; StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
• Publishing year: 2015
• Language: English
• Pages: 10-10
• Publication/Series: BMC Hematology
• Volume: 15
• Links: http://www.ncbi.nlm.nih.gov/pubmed/26167286?dopt=Abstract; http://dx.doi.org/10.1186/s12878-015-0029-1
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Hematology
• Status: Published
• ISBN/ISSN/Other: ISSN: 2052-1839